Cynthia Basu

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Nizar J. Bahlis, Caitlin Costello, Noopur Raje et al. · Nature Medicine · 2023 · 142 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

Margaret Gamalo, Jasmina Savić, Cynthia Basu et al. · Pharmaceutical Statistics · 2017 · 92 citations

Public Health, Biostatistics, Pediatrics +17

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Michaël Sébag, Noopur Raje, Nizar J. Bahlis et al. · Blood · 2021 · 55 citations

Life Sciences, Immunology, Pharmacology +16

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar J. Bahlis, Caitlin Costello et al. · Blood · 2022 · 46 citations

Medicine, Immunology, Oncology +16

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur Raje, Andrzej Jakubowiak, Cristina Gasparetto et al. · Blood · 2019 · 44 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17